Analgesic effects of p38 kinase inhibitor treatment on bone fracture healing

Jessica A. Cottrell, Markus Meyenhofer, Satyanarayana Medicherla, Linda Higgins, James O'Connor

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Traditional and COX-2 selective non-steroidal anti-inflammatory drug (NSAID) treatment inhibits fracture healing in animal models. This indicates that either the inflammatory phase following a bone fracture is necessary for efficient or sufficient bone regeneration to heal the fracture or COX-2 may have a specific function during bone regeneration unrelated to inflammation. These observations also indicate that NSAID use during fracture healing may be contra-indicated. Thus, identification of different analgesics for fracture pain or other orthopaedic surgical procedures would be of significant clinical benefit. Inhibitors of p38 kinase also have significant analgesic properties. However, p38 kinase is a critical regulator of inflammation. To assess the potential use of p38 kinase inhibition as a therapeutic strategy to manage fracture pain, the analgesic properties of SCIO-469, a p38α kinase inhibitor, were assessed in a rat fracture model and compared to other common analgesics. In addition, the effects of SCIO-469 treatment on ultimate fracture healing outcomes were measured by radiography and torsional mechanical testing. The data indicate that SCIO-469 was an effective analgesic. No adverse events related to fracture healing were observed in rats treated with SCIO-469. Immunohistochemistry showed that p38 kinase is activated primarily in the first days following a fracture. These observations suggest that p38α kinase inhibition may be an effective therapeutic strategy to manage orthopaedic-related pain. These observations also indicate that COX-2 has a specific function during bone regeneration other than promoting inflammation.

Original languageEnglish (US)
Pages (from-to)116-126
Number of pages11
JournalPain
Volume142
Issue number1-2
DOIs
StatePublished - Mar 1 2009

Fingerprint

Fracture Healing
Bone Fractures
Analgesics
Phosphotransferases
Bone Regeneration
Inflammation
Pain
Anti-Inflammatory Agents
Therapeutics
Orthopedic Procedures
Radiography
Pharmaceutical Preparations
Orthopedics
Animal Models
Immunohistochemistry
SCIO-469

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Neurology
  • Anesthesiology and Pain Medicine

Keywords

  • Analgesia
  • Animal model
  • Bone regeneration
  • Fracture healing
  • Pain management
  • Pain model
  • p38 kinase

Cite this

Cottrell, J. A., Meyenhofer, M., Medicherla, S., Higgins, L., & O'Connor, J. (2009). Analgesic effects of p38 kinase inhibitor treatment on bone fracture healing. Pain, 142(1-2), 116-126. https://doi.org/10.1016/j.pain.2008.12.019
Cottrell, Jessica A. ; Meyenhofer, Markus ; Medicherla, Satyanarayana ; Higgins, Linda ; O'Connor, James. / Analgesic effects of p38 kinase inhibitor treatment on bone fracture healing. In: Pain. 2009 ; Vol. 142, No. 1-2. pp. 116-126.
@article{c712bcbb53664e7889ff8efffc787f89,
title = "Analgesic effects of p38 kinase inhibitor treatment on bone fracture healing",
abstract = "Traditional and COX-2 selective non-steroidal anti-inflammatory drug (NSAID) treatment inhibits fracture healing in animal models. This indicates that either the inflammatory phase following a bone fracture is necessary for efficient or sufficient bone regeneration to heal the fracture or COX-2 may have a specific function during bone regeneration unrelated to inflammation. These observations also indicate that NSAID use during fracture healing may be contra-indicated. Thus, identification of different analgesics for fracture pain or other orthopaedic surgical procedures would be of significant clinical benefit. Inhibitors of p38 kinase also have significant analgesic properties. However, p38 kinase is a critical regulator of inflammation. To assess the potential use of p38 kinase inhibition as a therapeutic strategy to manage fracture pain, the analgesic properties of SCIO-469, a p38α kinase inhibitor, were assessed in a rat fracture model and compared to other common analgesics. In addition, the effects of SCIO-469 treatment on ultimate fracture healing outcomes were measured by radiography and torsional mechanical testing. The data indicate that SCIO-469 was an effective analgesic. No adverse events related to fracture healing were observed in rats treated with SCIO-469. Immunohistochemistry showed that p38 kinase is activated primarily in the first days following a fracture. These observations suggest that p38α kinase inhibition may be an effective therapeutic strategy to manage orthopaedic-related pain. These observations also indicate that COX-2 has a specific function during bone regeneration other than promoting inflammation.",
keywords = "Analgesia, Animal model, Bone regeneration, Fracture healing, Pain management, Pain model, p38 kinase",
author = "Cottrell, {Jessica A.} and Markus Meyenhofer and Satyanarayana Medicherla and Linda Higgins and James O'Connor",
year = "2009",
month = "3",
day = "1",
doi = "https://doi.org/10.1016/j.pain.2008.12.019",
language = "English (US)",
volume = "142",
pages = "116--126",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "1-2",

}

Cottrell, JA, Meyenhofer, M, Medicherla, S, Higgins, L & O'Connor, J 2009, 'Analgesic effects of p38 kinase inhibitor treatment on bone fracture healing', Pain, vol. 142, no. 1-2, pp. 116-126. https://doi.org/10.1016/j.pain.2008.12.019

Analgesic effects of p38 kinase inhibitor treatment on bone fracture healing. / Cottrell, Jessica A.; Meyenhofer, Markus; Medicherla, Satyanarayana; Higgins, Linda; O'Connor, James.

In: Pain, Vol. 142, No. 1-2, 01.03.2009, p. 116-126.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Analgesic effects of p38 kinase inhibitor treatment on bone fracture healing

AU - Cottrell, Jessica A.

AU - Meyenhofer, Markus

AU - Medicherla, Satyanarayana

AU - Higgins, Linda

AU - O'Connor, James

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Traditional and COX-2 selective non-steroidal anti-inflammatory drug (NSAID) treatment inhibits fracture healing in animal models. This indicates that either the inflammatory phase following a bone fracture is necessary for efficient or sufficient bone regeneration to heal the fracture or COX-2 may have a specific function during bone regeneration unrelated to inflammation. These observations also indicate that NSAID use during fracture healing may be contra-indicated. Thus, identification of different analgesics for fracture pain or other orthopaedic surgical procedures would be of significant clinical benefit. Inhibitors of p38 kinase also have significant analgesic properties. However, p38 kinase is a critical regulator of inflammation. To assess the potential use of p38 kinase inhibition as a therapeutic strategy to manage fracture pain, the analgesic properties of SCIO-469, a p38α kinase inhibitor, were assessed in a rat fracture model and compared to other common analgesics. In addition, the effects of SCIO-469 treatment on ultimate fracture healing outcomes were measured by radiography and torsional mechanical testing. The data indicate that SCIO-469 was an effective analgesic. No adverse events related to fracture healing were observed in rats treated with SCIO-469. Immunohistochemistry showed that p38 kinase is activated primarily in the first days following a fracture. These observations suggest that p38α kinase inhibition may be an effective therapeutic strategy to manage orthopaedic-related pain. These observations also indicate that COX-2 has a specific function during bone regeneration other than promoting inflammation.

AB - Traditional and COX-2 selective non-steroidal anti-inflammatory drug (NSAID) treatment inhibits fracture healing in animal models. This indicates that either the inflammatory phase following a bone fracture is necessary for efficient or sufficient bone regeneration to heal the fracture or COX-2 may have a specific function during bone regeneration unrelated to inflammation. These observations also indicate that NSAID use during fracture healing may be contra-indicated. Thus, identification of different analgesics for fracture pain or other orthopaedic surgical procedures would be of significant clinical benefit. Inhibitors of p38 kinase also have significant analgesic properties. However, p38 kinase is a critical regulator of inflammation. To assess the potential use of p38 kinase inhibition as a therapeutic strategy to manage fracture pain, the analgesic properties of SCIO-469, a p38α kinase inhibitor, were assessed in a rat fracture model and compared to other common analgesics. In addition, the effects of SCIO-469 treatment on ultimate fracture healing outcomes were measured by radiography and torsional mechanical testing. The data indicate that SCIO-469 was an effective analgesic. No adverse events related to fracture healing were observed in rats treated with SCIO-469. Immunohistochemistry showed that p38 kinase is activated primarily in the first days following a fracture. These observations suggest that p38α kinase inhibition may be an effective therapeutic strategy to manage orthopaedic-related pain. These observations also indicate that COX-2 has a specific function during bone regeneration other than promoting inflammation.

KW - Analgesia

KW - Animal model

KW - Bone regeneration

KW - Fracture healing

KW - Pain management

KW - Pain model

KW - p38 kinase

UR - http://www.scopus.com/inward/record.url?scp=60249083515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60249083515&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.pain.2008.12.019

DO - https://doi.org/10.1016/j.pain.2008.12.019

M3 - Article

VL - 142

SP - 116

EP - 126

JO - Pain

JF - Pain

SN - 0304-3959

IS - 1-2

ER -